Literature DB >> 9144727

Spray dried powders and powder blends of recombinant human deoxyribonuclease (rhDNase) for aerosol delivery.

H K Chan1, A Clark, I Gonda, M Mumenthaler, C Hsu.   

Abstract

PURPOSE: We have used rhDNase to investigate the feasibility of developing a dry protein powder aerosol for inhalation delivery.
METHODS: Powders of rhDNase alone and with sodium chloride were prepared by spray drying. Powder blends were obtained by mixing (tumbling and sieving) pure rhDNase powder with 'carrier' materials (lactose, mannitol or sodium chloride). The weight percent of drug in the blends was between 5 and 70%. The particle size distributions and crystallinity of the spray dried powders were obtained by laser diffraction and X-ray powder diffraction, respectively. Particle morphology was examined by scanning electron microscopy. The ability of the powders and powder blends to be dispersed into respirable aerosols was measured using a Rotahaler connected to a multistage liquid impinger operating at 60 L/min.
RESULTS: Pure rhDNase powder was quite cohesive with a fine particle fraction (FPF or "respirable fraction': % wt. of particles < 7 microns in the aerosol cloud) of about 20%. When particles also contained NaCl, the powders were dispersed better to form aerosols. A linear relationship was observed between the NaCl content and FPF for a similar primary size (approximately 3 microns volume median diameter) of particles. The particle morphology of these powders varied systematically with the salt content. For the blends, SEM revealed a monolayer-like adhesion of the fine drug particles to the carriers at drug contents > or = 50% wt. An overall 2-fold increase in FPF of rhDNase in the aerosol cloud was obtained for all the blends compared to the pure drug aerosols.
CONCLUSIONS: The aerosol properties of spray dried rhDNase powders can be controlled by incorporation of a suitable excipient, such as NaCl, and its relative proportion. Coarse carriers can also enhance the performance of rhDNase dry powder aerosols.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9144727     DOI: 10.1023/a:1012035113276

Source DB:  PubMed          Journal:  Pharm Res        ISSN: 0724-8741            Impact factor:   4.200


  5 in total

1.  Dry powder aerosols. I. A new powder inhalation device.

Authors:  J H Bell; P S Hartley; J S Cox
Journal:  J Pharm Sci       Date:  1971-10       Impact factor: 3.534

2.  Interparticle forces in binary and ternary ordered powder mixes.

Authors:  J N Staniforth; J E Rees; F K Lai; J A Hersey
Journal:  J Pharm Pharmacol       Date:  1982-03       Impact factor: 3.765

3.  Characterization of aerosols of human recombinant deoxyribonuclease I (rhDNase) generated by jet nebulizers.

Authors:  D Cipolla; I Gonda; S J Shire
Journal:  Pharm Res       Date:  1994-04       Impact factor: 4.200

4.  Feasibility study on spray-drying protein pharmaceuticals: recombinant human growth hormone and tissue-type plasminogen activator.

Authors:  M Mumenthaler; C C Hsu; R Pearlman
Journal:  Pharm Res       Date:  1994-01       Impact factor: 4.200

5.  Effect of aerosolized recombinant human DNase on exacerbations of respiratory symptoms and on pulmonary function in patients with cystic fibrosis. The Pulmozyme Study Group.

Authors:  H J Fuchs; D S Borowitz; D H Christiansen; E M Morris; M L Nash; B W Ramsey; B J Rosenstein; A L Smith; M E Wohl
Journal:  N Engl J Med       Date:  1994-09-08       Impact factor: 91.245

  5 in total
  18 in total

1.  Formation and isolation of spherical fine protein microparticles through lyophilization of protein-poly(ethylene glycol) aqueous mixture.

Authors:  T Morita; Y Horikiri; H Yamahara; T Suzuki; H Yoshino
Journal:  Pharm Res       Date:  2000-11       Impact factor: 4.200

2.  Use of solid corrugated particles to enhance powder aerosol performance.

Authors:  N Y Chew; H K Chan
Journal:  Pharm Res       Date:  2001-11       Impact factor: 4.200

3.  Predicting the quality of powders for inhalation from surface energy and area.

Authors:  David Cline; Richard Dalby
Journal:  Pharm Res       Date:  2002-09       Impact factor: 4.200

4.  Generation of fine powders of recombinant human deoxyribonuclease using the aerosol solvent extraction system.

Authors:  Rana T Bustami; Hak-Kim Chan; Theresa Sweeney; Fariba Dehghani; Neil R Foster
Journal:  Pharm Res       Date:  2003-12       Impact factor: 4.200

5.  Statistical modeling of protein spray drying at the lab scale.

Authors:  Kristin B Prinn; Henry R Costantino; Mark Tracy
Journal:  AAPS PharmSciTech       Date:  2002       Impact factor: 3.246

6.  Protein powders for encapsulation: a comparison of spray-freeze drying and spray drying of darbepoetin alfa.

Authors:  Xichdao C Nguyen; John D Herberger; Paul A Burke
Journal:  Pharm Res       Date:  2004-03       Impact factor: 4.200

7.  Formation of protein nano-matrix particles with controlled surface architecture for respiratory drug delivery.

Authors:  Philip Chi Lip Kwok; Amolnat Tunsirikongkon; William Glover; Hak-Kim Chan
Journal:  Pharm Res       Date:  2010-12-07       Impact factor: 4.200

8.  How much particle surface corrugation is sufficient to improve aerosol performance of powders?

Authors:  Nora Y K Chew; Patricia Tang; Hak-Kim Chan; Judy A Raper
Journal:  Pharm Res       Date:  2005-01       Impact factor: 4.200

Review 9.  Particle engineering for pulmonary drug delivery.

Authors:  Albert H L Chow; Henry H Y Tong; Pratibhash Chattopadhyay; Boris Y Shekunov
Journal:  Pharm Res       Date:  2007-03       Impact factor: 4.200

10.  Protein deposition from dry powder inhalers: fine particle multiplets as performance modifiers.

Authors:  P Lucas; K Anderson; J N Staniforth
Journal:  Pharm Res       Date:  1998-04       Impact factor: 4.200

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.